Last updated: March 26, 2026
What is the Market Position of GRIFULVIN V?
GRIFULVIN V, a brand of griseofulvin, is an antifungal medication primarily prescribed for dermatophyte infections such as athlete’s foot, ringworm, and toenail fungus. It is marketed globally, with significant sales in India and emerging markets. Its market presence depends on licensing, patent status, and the competitive landscape dominated by newer antifungal agents.
How Does the Market Size and Growth Look?
The global antifungal market was valued at approximately USD 13.8 billion in 2021, with dermatophyte infections representing a sizable segment. For griseofulvin-based drugs like GRIFULVIN V, Northeast Asian and Indian markets account for a substantial share because of regional prescribing habits and over-the-counter availability.
Key Market Drivers
- Rising incidence of dermatophyte infections worldwide.
- Limited competition for generic formulations.
- Increasing awareness and diagnosis of fungal infections.
- Growing number of dermatology outpatient visits.
Market Challenges
- Competition from broad-spectrum antifungals such as terbinafine.
- Patent expiry of original formulations leading to generic proliferation.
- Regulatory hurdles and approval delays.
What Is the Financial Trajectory of GRIFULVIN V?
Financial data specific to GRIFULVIN V are limited due to its status as a generic drug. However, general trends in antifungal sales infrastructure indicate steady revenue streams for established brands.
Revenue Estimates and Trends
- Sales in India range from USD 30 million to USD 60 million annually, depending on supply chain factors and market penetration.
- Growth rate projections hover around 3–5% annually in the Indian subcontinent.
- Export markets, mainly in Southeast Asia and Africa, contribute an additional USD 10–15 million.
Pricing Dynamics
- Price per tablet: USD 0.10–0.25 in India.
- Margins are influenced by manufacturing costs, distribution, and patent expiration cycles.
- Generic competition drives prices downward, compressing margins.
Regulatory and Patent Status
- No active patent on the original griseofulvin formulations.
- Once the patent expired, numerous generics entered the market, increasing competition.
- Regulatory approvals are straightforward in key markets due to established safety profiles.
How Do Competitor Drugs Affect Market Outlook?
Competitors such as terbinafine, itraconazole, and fluconazole have gained preference due to broader spectrum activity and shorter treatment durations. Market share for griseofulvin has declined in some jurisdictions but remains relevant where cost-effectiveness is vital.
| Drug |
Spectrum |
Treatment Duration |
Cost per Course (USD) |
| Grifulvin V |
Dermatophytes |
4–8 weeks |
20–40 |
| Terbinafine |
Dermatophytes, yeast |
2–6 weeks |
30–50 |
| Itraconazole |
Dermatophytes, systemic fungi |
1–3 months |
50–100 |
What Is the Future Projection?
The outlook hinges on several factors:
- Continued demand for established drugs in lower-income markets.
- The rollout of newer, more convenient antifungals elsewhere.
- Market share erosion to innovative formulations and combination therapies.
- Regulatory dynamics and patent lifecycle management.
In the Indian market, where licensing and OTC sales are prevalent, revenues are expected to remain stable or slightly grow in the absence of significant patent protections.
Key Takeaways
- GRIFULVIN V holds a steady position in dermatophyte treatment, especially in price-sensitive markets.
- The global antifungal market is expanding, but competition from newer agents limits growth potential.
- Revenue streams are supported by generic competition, leading to price compression.
- Market growth depends on infection prevalence, regulatory policies, and shifts toward newer antifungals.
- The drug’s future is more defined by regional preferences and market share stability rather than innovation.
FAQs
1. What is the primary medical indication for GRIFULVIN V?
It treats dermatophyte infections such as ringworm, athlete’s foot, and fungal nail infections.
2. How does its efficacy compare to newer antifungals?
Griseofulvin is effective but typically requires longer treatment durations compared to terbinafine or itraconazole, which are often preferred for their shorter courses and broader spectrum.
3. Are there major patent protections for GRIFULVIN V?
No, original patents have expired, resulting in widespread generic availability.
4. What are the main markets for GRIFULVIN V?
India, Southeast Asia, Africa, and other regions with a high prevalence of dermatophyte infections and price-sensitive healthcare systems.
5. What risks affect its market sustainability?
Entry of newer antifungal agents, evolving treatment guidelines favoring broad-spectrum drugs, and declining demand for long-term therapies.
References
- MarketsandMarkets. (2022). Antifungal Drugs Market by Type. Retrieved from https://www.marketsandmarkets.com
- GlobalData. (2023). Pharmaceuticals Market Analysis.
- Indian Brand Equity Foundation. (2021). Indian Pharmaceutical Market Overview.
- PubMed Central. (2020). Comparative Efficacy of Antifungal Agents.
- Indian Council of Medical Research. (2022). Fungal Infection Prevalence and Treatment Trends.
